This website provides information about the business field of CO.DON GmbH, which has taken over the business operations from CO.DON AG.
Information on CO.DON Aktiengesellschaft can be found at www.codon-aktiengesellschaft.de.
Cartilage is the shock absorber in our joints. Joint pain may be due to a cartilage defect – an injury or damage to the cartilage. Accidents or overexertion may be the cause, but the defects can also result from natural wear and tear. Because cartilage cannot grow back, regenerative treatment is required to rebuild it. If it is left untreated, the defect could enlarge over time and the joint may deteriorate.
Our individualised cell therapies enable the regenerative treatment of articular cartilage defects using only autologous, i.e. the patient’s own cartilage cells. The cell transplants contain nothing foreign to the patient’s body. This method goes by the name of matrix-associated autologous chondrocyte transplantation, or M-ACT for short.
Biopsy: A minimally invasive operation is used to remove a small piece of cartilage from a healthy area of the joint concerned. It is then sent to us, along with a blood sample.
Cultivation: The chondrocytes are proliferated in a special process using the patient’s blood in our cleanroom facility. As they grow, they form small globules.
Transplantation: In a minimally invasive operation the cartilage globules are implanted into the defect, to which they naturally adhere. They form new cartilage that integrates with the existing, healthy cartilage.
Rehabilitation: Once the cartilage cells have been transplanted, a personal rehabilitation plan begins. Once the therapy has been completed, the newly formed tissue is comparable with healthy cartilage – the joint can bear weight again.
As a manufacturer of prescription-only pharmaceuticals, we are not allowed to provide detailed information due to legal regulations. For medical information on our cell therapies, please contact your doctor.